Brian Cheng
Stock Analyst at JP Morgan
(0.99)
# 3,570
Out of 4,784 analysts
64
Total ratings
32.69%
Success rate
-21.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $21.65 | - | 1 | Mar 27, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $22 → $15 | $6.32 | +137.34% | 3 | Mar 6, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $48.88 | +16.61% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $8.07 | +61.09% | 4 | Feb 28, 2025 | |
| BPMC Blueprint Medicines | Maintains: Overweight | $126 → $129 | $88.72 | +45.40% | 2 | Feb 4, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.18 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $1.25 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $12.37 | +45.51% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $11.23 | +149.33% | 4 | Nov 7, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $18.37 | +150.41% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $2.00 | +1,550.00% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.48 | +305.41% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $6.99 | +243.35% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.59 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.38 | +1,217.52% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.55 | +416.13% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $10.38 | +44.51% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.37 | +3,650.33% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.49 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.83 | +622.72% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.43 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.17 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.73 | +1,056.07% | 2 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $11.58 | +634.02% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.86 | +167.18% | 1 | Aug 3, 2021 |
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $21.65
Upside: -
iTeos Therapeutics
Mar 6, 2025
Maintains: Overweight
Price Target: $22 → $15
Current: $6.32
Upside: +137.34%
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $48.88
Upside: +16.61%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $8.07
Upside: +61.09%
Blueprint Medicines
Feb 4, 2025
Maintains: Overweight
Price Target: $126 → $129
Current: $88.72
Upside: +45.40%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.18
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.25
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $12.37
Upside: +45.51%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $11.23
Upside: +149.33%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $18.37
Upside: +150.41%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $2.00
Upside: +1,550.00%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.48
Upside: +305.41%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $6.99
Upside: +243.35%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.59
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.38
Upside: +1,217.52%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.55
Upside: +416.13%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $10.38
Upside: +44.51%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.37
Upside: +3,650.33%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.83
Upside: +622.72%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.43
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.17
Upside: -
Sep 2, 2021
Initiates: Overweight
Price Target: $20
Current: $1.73
Upside: +1,056.07%
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $11.58
Upside: +634.02%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.86
Upside: +167.18%